+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P04007(ADGRG2 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

ADGRG2 (Adhesion G Protein-Coupled Receptor G2), also known as GPR64. is a member of the adhesion GPCR family, characterized by a large extracellular N-terminal region containing adhesion-like domains and a seven-transmembrane helix structure typical of GPCRs. It plays roles in cellular signaling, tissue development, and cell-cell/matrix interactions, with expression observed in endothelial cells, immune cells, and specific epithelial tissues. ADGRG2 is implicated in physiological processes such as angiogenesis, immune regulation, and reproductive system function. Dysregulation of ADGRG2 has been linked to pathologies including prostate cancer, glioblastoma, and inflammatory disorders, highlighting its potential as a therapeutic target.

ADGRG2 antibodies are tools designed to detect, quantify, or inhibit this receptor in research and diagnostic contexts. These antibodies often target extracellular domains (e.g., the N-terminal fragment) or intracellular epitopes, enabling applications like Western blotting, immunohistochemistry, flow cytometry, and immunofluorescence. Monoclonal antibodies are preferred for specificity, while polyclonal antibodies may offer broader epitope recognition. Some ADGRG2 antibodies are engineered for functional studies, such as blocking ligand binding or modulating receptor activation. Validation typically includes testing in cell lines with confirmed ADGRG2 expression or knockout controls. As ADGRG2 gains attention in tumor microenvironment studies and biomarker discovery, reliable antibodies are critical for exploring its role in disease mechanisms and therapeutic development.